GlassScriptPhysician profile
George Prica
NPI 1578637567
$9,178.64
in general payments reported to CMS, 2019-2025
35 companies · $2,363 in 2025
The $2,363 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $706 · 2021: $1,416 · 2022: $963 · 2023: $1,136 · 2024: $1,975 · 2025: $2,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,473.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,331.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $917.12 | 2020-2025 | Rexulti |
| Abbvie INC. | $842.42 | 2021-2025 | |
| Abbott Laboratories | $795.29 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $693.10 | 2019-2025 | Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $503.22 | 2024-2025 | Auvelity, Symbravo |
| Glaxosmithkline, LLC. | $430.77 | 2022-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $314.38 | 2023-2025 | Mounjaro, Zepbound |
| Amgen INC. | $274.08 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $245.03 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $230.95 | 2024-2025 | Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $223.20 | 2020-2023 | Qelbree |
| Allergan, INC. | $212.46 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.08 | 2022-2024 | Caplyta |
| Alkermes, INC. | $170.10 | 2021-2023 | Lybalvi |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $169.06 | 2024 | Voquezna |
| Sunovion Pharmaceuticals INC. | $138.94 | 2019-2020 | |
| Medtronic, INC. | $136.32 | 2024 | Signia |
| Bayer Healthcare Pharmaceuticals INC. | $119.56 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $116.17 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $112.54 | 2024 | |
| Neurocrine Biosciences, INC. | $112.10 | 2021 | |
| Jazz Pharmaceuticals INC. | $106.51 | 2021 | |
| Nestle Healthcare Nutrition INC. | $106.24 | 2022 | |
| Corium, LLC | $103.66 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $100.50 | 2021 | |
| Dexcom, INC. | $94.35 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.77 | 2022-2023 | |
| Sk Life Science, INC. | $83.68 | 2022 | |
| Radius Health, INC. | $76.80 | 2020 | |
| Pfizer INC. | $44.81 | 2019 | |
| Boston Scientific Corporation | $26.17 | 2024 | Wavewriter Alpha Prime 16 |
| Exact Sciences Corporation | $21.77 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $19.15 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $18.32 | 2025 | Capvaxive, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Prica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.